Study Details

Back
Study ID 905-EC-012
Study Title Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Patients who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms
Clinicaltrials.gov Identifier NCT01908829
Compound Name EB178 / mirabegron + solifenacin succinate
Medical Indication or Disease Overactive bladder
Study Sponsor Astellas Pharma Europe Ltd
Collaborator Not Applicable
Study Start Date 10-Jul-2013
Study Completion Date 25-Nov-2014
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS